FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018082261> ?p ?o ?g. }

• W2018082261 endingPage "292" @default.
• W2018082261 startingPage "291" @default.
• W2018082261 abstract "Sirs, We read with great interest the paper by Briani et al.1 evaluated the prevalence of antiganglioside antibodies (namely, GM1, GM2, GD1a and GD1b) in children with coeliac disease (CD). Of the 42 CD patients enrolled in this study, only two (5%) were found positive for antiganglioside antibodies. The two patients had no evidence of neurological manifestations and therefore the authors concluded that antiganglioside antibodies found in CD are not related with neurological dysfunction. These findings are in contrast with previously published data2 and recent results from our laboratory. Using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (IMMCO Diagnostics, Buffalo, NY, USA), we investigated anti-GM1, -GD1b and -GQ1b IgG antibodies in 22 adult patients (median age 35, range: 19–56 years; three males, 19 females) with CD and neurological manifestations, including eight cases of gluten ataxia, seven epilepsy, two multiple sclerosis, three attention/memory impairment and two peripheral neuropathy. Furthermore, antiganglioside antibodies were sought in 10 CD patients (median age 37, range: 17–59 years; two males, eight females) without neurological dysfunction and 10 age- and sex-matched blood donors. The results of antiganglioside antibody detection are summarized in Table 1. The prevalence of anti-GM1 and -GD1b was found to be higher (although not statistically significant) in CD patients with neurological dysfunction than in those without neurological involvement. Interestingly, of the eight patients with neurological manifestations related to CD, six had a form of epilepsy without occipital calcifications, whereas the remaining two had gluten ataxia and peripheral neuropathy, respectively. Antibodies to GQ1b showed a very low prevalence in each of the investigated groups. The present findings, showing positivity of antiganglioside antibodies, confirm and expand the identification of antineuronal antibodies (i.e. Hu-like and Yo-like) in patients with CD with neurological complications.3,4 Conversely to Briani et al.,1 our results suggest a correlation between antiganglioside antibodies and CD with neurological complications. The reason for this discrepancy may be ascribed to the higher prevalence of neurological manifestations in adulthood rather than in childhood CD.5 Antiganglioside antibodies may represent a new immunological marker to identify neurological involvement in patients with CD." @default.
• W2018082261 created "2016-06-24" @default.
• W2018082261 creator A5029721718 @default.
• W2018082261 creator A5045484405 @default.
• W2018082261 creator A5082448644 @default.
• W2018082261 date "2005-01-18" @default.
• W2018082261 modified "2023-10-15" @default.
• W2018082261 title "Antibodies to gangliosides in coeliac disease with neurological manifestations" @default.
• W2018082261 cites W1995546167 @default.
• W2018082261 cites W2011414563 @default.
• W2018082261 cites W2054536605 @default.
• W2018082261 cites W2104661738 @default.
• W2018082261 cites W2146173723 @default.
• W2018082261 doi "https://doi.org/10.1111/j.1365-2036.2005.02291.x" @default.
• W2018082261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15691306" @default.
• W2018082261 hasPublicationYear "2005" @default.
• W2018082261 type Work @default.
• W2018082261 sameAs 2018082261 @default.
• W2018082261 citedByCount "7" @default.
• W2018082261 countsByYear W20180822612018 @default.
• W2018082261 countsByYear W20180822612019 @default.
• W2018082261 countsByYear W20180822612021 @default.
• W2018082261 countsByYear W20180822612023 @default.
• W2018082261 crossrefType "journal-article" @default.
• W2018082261 hasAuthorship W2018082261A5029721718 @default.
• W2018082261 hasAuthorship W2018082261A5045484405 @default.
• W2018082261 hasAuthorship W2018082261A5082448644 @default.
• W2018082261 hasBestOaLocation W20180822611 @default.
• W2018082261 hasConcept C118552586 @default.
• W2018082261 hasConcept C126322002 @default.
• W2018082261 hasConcept C134018914 @default.
• W2018082261 hasConcept C159654299 @default.
• W2018082261 hasConcept C163764329 @default.
• W2018082261 hasConcept C203014093 @default.
• W2018082261 hasConcept C2778186239 @default.
• W2018082261 hasConcept C2779134260 @default.
• W2018082261 hasConcept C2779901536 @default.
• W2018082261 hasConcept C2780349322 @default.
• W2018082261 hasConcept C2780640218 @default.
• W2018082261 hasConcept C2780906641 @default.
• W2018082261 hasConcept C555293320 @default.
• W2018082261 hasConcept C71924100 @default.
• W2018082261 hasConcept C90924648 @default.
• W2018082261 hasConceptScore W2018082261C118552586 @default.
• W2018082261 hasConceptScore W2018082261C126322002 @default.
• W2018082261 hasConceptScore W2018082261C134018914 @default.
• W2018082261 hasConceptScore W2018082261C159654299 @default.
• W2018082261 hasConceptScore W2018082261C163764329 @default.
• W2018082261 hasConceptScore W2018082261C203014093 @default.
• W2018082261 hasConceptScore W2018082261C2778186239 @default.
• W2018082261 hasConceptScore W2018082261C2779134260 @default.
• W2018082261 hasConceptScore W2018082261C2779901536 @default.
• W2018082261 hasConceptScore W2018082261C2780349322 @default.
• W2018082261 hasConceptScore W2018082261C2780640218 @default.
• W2018082261 hasConceptScore W2018082261C2780906641 @default.
• W2018082261 hasConceptScore W2018082261C555293320 @default.
• W2018082261 hasConceptScore W2018082261C71924100 @default.
• W2018082261 hasConceptScore W2018082261C90924648 @default.
• W2018082261 hasIssue "3" @default.
• W2018082261 hasLocation W20180822611 @default.
• W2018082261 hasLocation W20180822612 @default.
• W2018082261 hasOpenAccess W2018082261 @default.
• W2018082261 hasPrimaryLocation W20180822611 @default.
• W2018082261 hasRelatedWork W2011762866 @default.
• W2018082261 hasRelatedWork W2014832572 @default.
• W2018082261 hasRelatedWork W2028715494 @default.
• W2018082261 hasRelatedWork W2073269240 @default.
• W2018082261 hasRelatedWork W2075040702 @default.
• W2018082261 hasRelatedWork W2110438573 @default.
• W2018082261 hasRelatedWork W2136870774 @default.
• W2018082261 hasRelatedWork W2197774694 @default.
• W2018082261 hasRelatedWork W2416202286 @default.
• W2018082261 hasRelatedWork W2604923520 @default.
• W2018082261 hasVolume "21" @default.
• W2018082261 isParatext "false" @default.
• W2018082261 isRetracted "false" @default.
• W2018082261 magId "2018082261" @default.
• W2018082261 workType "article" @default.